Published in Ann Oncol on February 24, 2006
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med (2010) 1.55
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
Targeting BRAF in thyroid cancer. Br J Cancer (2006) 1.08
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs (2010) 0.99
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs (2009) 0.93
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One (2012) 0.92
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther (2009) 0.89
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer (2008) 0.87
Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget (2013) 0.86
Molecular therapies for malignant glioma. Wien Med Wochenschr (2006) 0.81
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs (2012) 0.81
Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. Invest New Drugs (2007) 0.80
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel) (2014) 0.78
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med (2011) 0.75
Investigational approaches for mesothelioma. Front Oncol (2011) 0.75
Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. Chin J Cancer Res (2015) 0.75
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.75
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. Oncotarget (2017) 0.75
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol (2017) 0.75
Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med (1996) 8.41
Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med (1992) 6.29
The maintenance of key pecking by stimulus-contingent and response-independent food presentation. J Exp Anal Behav (1973) 6.12
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J (1999) 5.88
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Two different kinds of key peck in the pigeon: some properties of responses maintained by negative and positive response-reinforcer contingencies. J Exp Anal Behav (1972) 3.57
The role of the response-reinforcer contingency in negative automaintenance. J Exp Anal Behav (1972) 3.52
High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A (1999) 3.31
Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician (1997) 3.29
Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. Acute Renal Failure Investigation Team. JAMA (1998) 3.28
Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage (1996) 3.26
Evaluation of an algorithm for integrated management of childhood illness in an area of Kenya with high malaria transmission. Bull World Health Organ (1997) 3.20
emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis (1999) 3.12
Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet (1989) 3.09
Effects of reinforcement magnitude on pigeons' preference for different fixed-ratio schedules of reinforcement. J Exp Anal Behav (1969) 3.04
Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol (2001) 2.92
Analysis of clinical and food-borne isolates of Listeria monocytogenes in the United States by multilocus enzyme electrophoresis and application of the method to epidemiologic investigations. Appl Environ Microbiol (1990) 2.90
Development of complex, stereotyped behavior in pigeons. J Exp Anal Behav (1980) 2.85
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta (1998) 2.83
Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis (1999) 2.69
The social psychology of the gift. AJS (1967) 2.63
Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. JAMA (1997) 2.62
Survey of emm gene sequences and T-antigen types from systemic Streptococcus pyogenes infection isolates collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995. J Clin Microbiol (1997) 2.55
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer (2005) 2.49
Discriminative stimulus location as a determinant of positive and negative behavioral contrast in the pigeon. J Exp Anal Behav (1975) 2.47
Maintenance of key pecking by response-independent food presentation: the role of the modality of the signal for food. J Exp Anal Behav (1973) 2.42
Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics (1999) 2.34
Photogrammetric measurement of nerve fiber layer thickness. Ophthalmology (1989) 2.34
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Discrete-trials spaced responding in the pigeon: the dependence of efficient performance on the availability of a stimulus for collateral pecking. J Exp Anal Behav (1971) 2.31
Analysis of Listeria monocytogenes by multilocus enzyme electrophoresis and application of the method to epidemiologic investigations. Int J Food Microbiol (1989) 2.29
Behavioral contrast in the pigeon: a study of the duration of key pecking maintained on multiple schedules of reinforcement. J Exp Anal Behav (1975) 2.19
Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr (1996) 2.17
Failure to produce response variability with reinforcement. J Exp Anal Behav (1982) 2.07
Identifying sick children requiring referral to hospital in Bangladesh. Bull World Health Organ (1997) 2.00
Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies. Pediatr Infect Dis J (1995) 2.00
Prognosis and treatment of disseminated uveal melanoma. Cancer (1993) 1.98
Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J (1993) 1.95
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry (1997) 1.93
Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nat Med (1999) 1.92
Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology (2000) 1.92
Post-neonatal health and development of children born after assisted reproduction: a systematic review of controlled studies. Eur J Obstet Gynecol Reprod Biol (2006) 1.92
Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics (2000) 1.91
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer (2012) 1.90
Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis (2000) 1.89
Why do physicians prescribe antibiotics for children with upper respiratory tract infections? JAMA (1998) 1.89
Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis (1995) 1.88
Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics (1999) 1.85
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol (1998) 1.80
MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis. Mol Microbiol (2001) 1.79
Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ (1998) 1.72
Pallor of the optic disc. Quantitative photographic evaluation. Arch Ophthalmol (1973) 1.71
Changing immunization referral patterns among pediatricians and family practice physicians, Dallas County, Texas, 1988. Pediatrics (1991) 1.69
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol (2002) 1.68
Evaluation of the Etest as a means of determining the antibiotic susceptibilities of isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in the Central African Republic. J Antimicrob Chemother (2000) 1.67
Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell (1994) 1.67
Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem (2001) 1.65
Appropriate use of antibiotics for URIs in children: Part I. Otitis media and acute sinusitis. The Pediatric URI Consensus Team. Am Fam Physician (1998) 1.64
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann Oncol (1997) 1.63
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol (2004) 1.59
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs (1996) 1.56
Current attitudes regarding use of antimicrobial agents: results from physician's and parents' focus group discussions. Clin Pediatr (Phila) (1998) 1.55
Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet (2001) 1.54
Hospital-acquired invasive group a streptococcal infections in Ontario, Canada, 1992-2000. Clin Infect Dis (2005) 1.54
Sensory maps in the human brain. Nature (1994) 1.54
Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res (1998) 1.54
Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol (2001) 1.50
The structure of the C-terminal domain of methionine synthase: presenting S-adenosylmethionine for reductive methylation of B12. Structure (1996) 1.49
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993. Nucleic Acids Res (1993) 1.49
Emergency department overcrowding following systematic hospital restructuring: trends at twenty hospitals over ten years. Acad Emerg Med (2001) 1.48
Measurement of the depth of maximum of extensive air showers above 10{18} eV. Phys Rev Lett (2010) 1.48
Studies of operant and reflexive key pecks in the pigeon. J Exp Anal Behav (1977) 1.48
Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. Int J Clin Pharmacol Ther (2010) 1.47
House dust mite sensitization in children and residential characteristics in a temperate region. J Allergy Clin Immunol (1991) 1.47
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol (1997) 1.46
Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg (1998) 1.46
Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res (1996) 1.44
Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med (1999) 1.43
Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. Gene (2001) 1.42
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer (2006) 1.42
Novel tumor suppressor locus in human chromosome region 3p14.2. J Natl Cancer Inst (1999) 1.42
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler (2008) 1.42
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem (2000) 1.42
Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis (1989) 1.41
Glaucomalike disks without increased intraocular pressure or visual field loss. Am J Ophthalmol (1989) 1.41
Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol (1991) 1.41